[Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.]

[Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.] Abstract Text:

Joaquin Belon,Jose Manuel Cervera,Antonia Martinez,Angela Lopez,

Cancer- and chemotherapy-induced anemia is a common complication that arises in virtually all oncology branches. Darbepoetin alfa (Aranesp(R)), a novel erythropoiesis-stimulating protein, is a drug appropriate for treatment of anemia and chemotherapy-induced anemia in cancer patients. Aim: In order to audit the clinical use of darbepoetin alfa in oncology practice in Spain, we conducted a questionnaire-based analysis of darbepoetin alfa at a fixed dose of 150 mcg s.c. once weekly in patients who were receiving chemotherapy with or without other anti-cancer therapies. Design: Cohort-based retrospective study involving patients from 40 Spanish health centers. Patients: The records of 666 patients with median age of 60.37 (range: 16-100 years) of both sexes (men 41%; women 59%) were included in this study. The most frequent types of tumors were: breast (20%), ovarian (15.2%), lung (14.5%), colorectal (10.5%) hematologic (6.8%), and head and neck (6.2%), with a higher percentage of stage IV disease (60.6%). Results: Most patients were treated with platinum-based chemotherapy (35.7%), followed by taxanes (14.0%), combinations of platinum and taxanes (19.6%) or other therapies (30.7%). About 62.6% of patients received first-line chemotherapy, while 21.9% and 15.5% required second-line and third-line chemotherapy, respectively. The baseline hemoglobin concentration was <9 g/dl in 27.5% of the patients, between 9 and 10 g/dl in 36%, and >/=10 g/dl in 36.5% (including 5.1% of patients with hemoglobin >/=11 g/dl). The average treatment period with darbepoetin alfa was 8.9 weeks. The dose of the drug was increased at week 4 in 17.7% of the patients. At the end of the treatment, 83.8% of the patients had hemoglobin levels >/=10 g/dl and 56.5% were at >/=11 g/dl. Overall, hematopoietic response to darbepoetin alfa was unrelated tumor type, stage of disease, regimen or line of chemotherapy, or radiotherapy. The most relevant factors of choice for darbepoetin alfa were less frequent administration (84% of cases), rapid response (37%) and high efficacy (28%). Conclusions: Darbepoetin alfa 150 microg once weekly used for amelioration of chemotherapy-induced anemia effectively maintained hemoglobin levels in most patients within the daily oncology routine. Most of the oncologists participating in the study confirmed the willingness to prescribe darbepoetin alfa based on the convenience of a less frequent administration regimen. (c) 2006 Prous Science. All rights reserved.

[Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.] Publishing Authors By Initials

J Belon,JM Cervera,A Martinez,A Lopez,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

[Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.] Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Drugs of today (Barcelona, Spain : 1998)

VOLUME: 42 Suppl 10

Page Numbers: 1-12

Journal Abbreviation:

ISSN: 1699-3993

DAY: 11

MONTH: Jun

YEAR: 2006

[Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.] Information

Number of References:

LANGUAGE: spa

NlmUniqueID: 101160518

[Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.] Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: [Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.] Information

Substance Name:

Registry Number:

Grant and Affiliation Information for [Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.]

AFFILIATION: Hospital Virgen de las Nieves, Granada, Spain.

Country: Spain

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drugs Today (Barc)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Darbepoetin alfa at weekly fixed doses Clinical experience in Spanish centers Related Publications

• A unique mucin immunoenhancing peptide with antitumor properties.
• Comparative effects of nacre water-soluble matrix and dexamethasone on the alkaline phosphatase activity of MRC-5 fibroblasts.
• Copper, zinc, calcium and magnesium content of alcoholic beverages and by-products from Spain: nutritional supply.
• Cysticercosis in a female Nicaraguan traveler.
• Depression and anxiety in women with breast cancer and their partners.
• Determination of impurities in phenacetin by high-performance liquid chromatography.
• Differential mortality in Iran.
• Effect of branching and confinement on star-branched polymeric systems.
• Effect of kainic acid treatment on insulin-like growth factor-2 receptors in the IGF2-deficient adult mouse brain.
• Elevated resting [Ca(2+)](i) in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR.
• Essential role for platelets in organ injury and inflammation in resuscitated hemorrhagic shock.
• Evaluation of the quality of cause of death statistics in rural China using verbal autopsies.
• Family interventions for serious mental illness: translating research to practice.
• Igf2 deficiency results in delayed lung development at the end of gestation.
• Jugular vein catheterization for hemodialysis: correct positioning control using real-time ultrasound guidance.
• Microvesicle-associated tissue factor and Trousseau's syndrome.
• Neighborhood risk factors for obesity.
• Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse.
• Postdrinking sexual perceptions and behaviors toward another person: alcohol expectancy set and gender differences.
• Revision of chemotherapy in early stages neoadjuvant therapy.
• Scent may signal fighting ability in male Iberian rock lizards.
• Self-association processes involving anthracene labeled phosphatidylcholines in model membrane.
• Social networks, support, and psychosocial functioning among American Indian women in treatment.
• Substance abuse prevention intervention research with Hispanic populations.
• Tip position of long-term central venous access devices used for parenteral nutrition.
• Using bicellar mixtures to form supported and suspended lipid bilayers on silicon chips.
• Validation of cause-of-death statistics in urban China.
• [Darbepoetin alfa at weekly fixed doses. Clinical experience in Spanish centers.]
• [Postoperative serum vascular endothelial growth factor can be a marker for colorectal cancer recurrence]
• [Self-regulation systems to control tobacco advertising. An empirical analysis.]